Core Insights - Celcuity is a clinical stage company focused on developing drugs targeting the PAM pathway, specifically the PI3K/AKT/mTOR pathway, which is crucial in oncology [1] Group 1: Clinical Trials - The company has three ongoing trials, including a Phase III trial evaluating GEDA in combination with palbociclib and fulvestrant for women who have progressed on prior CDK therapy [1] - A first-line study is being conducted with the same drug combination for treatment-naive women with endocrine-resistant metastatic breast cancer [2] - A third study is in an earlier phase, investigating the drug combination with an androgen receptor inhibitor in men with castration-resistant prostate cancer [2]